Home


Rethink Tazarotene. Discover FABIOR Foam. The gentleness of a foam. The power of tazarotene. Fabior tazarotene foam, 0.1 percent, 50 grams, topical use, Mayne Pharma

Treat your patients’ acne with the power of tazarotene1

In clinical studies of once-daily FABIOR Foam used as monotherapy, patients with moderate-to-severe acne saw a 56.1% reduction in total acne lesions at week 12.

Learn more.

Give your patients the only topical retinoid acne treatment available in a foam1

FABIOR Foam is an aqueous-based, spreadable formulation that is easy to apply and absorbs quickly.2

Learn more.

Treating acne doesn’t have to be a balancing act

FABIOR Foam is effective acne therapy3

  • In 12-week studies of patients with moderate-to-severe acne, FABIOR Foam used once daily as monotherapy was effective at treating both inflammatory and non-inflammatory lesions

FABIOR Foam is well-tolerated3,4

  • Less than 3% of patients discontinued use of FABIOR Foam due to local skin reactions
  • The tolerability of FABIOR Foam is similar across gender, age group, race, and baseline severity

FABIOR Foam is convenient

  • FABIOR Foam is an aqueous-based, spreadable formulation that is easy to apply to both hair-bearing and non-hair-bearing skin5
  • Most insured, eligible patients will pay $0 for a FABIOR Foam prescription

References: 1. FABIOR Foam [package insert]. Greenville, NC: Mayne Pharma; 2016. 2. Rawlings AV, Lombard KJ. A review on the extensive skin benefits of mineral oil. Int J Cosmet Sci. 2012;34(6):511-518. 3. Data on file; Greenville, NC: Mayne Pharma LLC. 4. Stein Gold L, Jasper S. Tazarotene foam 0.1% for Acne Vulgaris: analysis of integrated efficacy and safety data by race. Presented at: Proceedings of the Summer Academy Meeting American Academy of Dermatology; August 15-19, 2012; Boston, MA. 5. Jarratt M, Werner CP, Alió Saenz AB. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. Clin Drug Investig. 2013;33(4):283-289.

Indication

FABIOR Foam is a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

For more information, please see full Prescribing Information and Patient Information Leaflet

Important Safety Information

  • FABIOR Foam is contraindicated in pregnancy. FABIOR Foam may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus. Females of child-bearing potential should be warned of the potential risk and use of adequate birth-control measures when tazarotene foam is used. The possibility of pregnancy should be considered in females of child-bearing potential at the time of institution of therapy.
  • FABIOR Foam should be used with caution in patients with history of local tolerability reactions or local hypersensitivity.
  • The propellant in FABIOR Foam is flammable. Instruct the patient to avoid fire, flame, and/or smoking during and immediately following application.
  • Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided when using FABIOR Foam. Patients must be warned to use sunscreens and protective clothing. Patients with sunburn should be advised not to use FABIOR Foam until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution. FABIOR Foam should be used with caution in patients with a personal or family history of skin cancer or if the patient is also taking drugs known to be photosensitizers.
  • FABIOR Foam may cause skin redness, peeling, burning, or excessive pruritus. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur. If skin irritation occurs, therapy with FABIOR Foam should be reduced to an interval the patient can tolerate, temporarily interrupted, or discontinued. In addition, dermatologic medications and cosmetics that have a strong drying effect should be avoided
  • Retinoids should not be used on abraded or eczematous skin, as they may cause severe irritation. Contact with the mouth, eyes, and mucous membranes should be avoided. Weather extremes, such as wind or cold, may be more irritating to patients using FABIOR Foam. Excessive topical application of FABIOR Foam may lead to marked redness, peeling, or discomfort.

Medical Information & Adverse Drug Events Reporting

To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.